| Abstract: |
Historically, immunotherapy has had limited impact in solid tumors with the exception of melanoma and renal cell carcinoma, which have been deemed as "immunologic cancers" given their potential for remissions either spontaneously or following removal of the primary lesion. Despite multiple immunologic approaches with peptide, protein, and DNA vaccines, no one therapy has induced complete remission or maintained durability of response. Sipuleucel-T represents one of several novel immunologic therapy approaches to treat prostate cancer in addition to other solid tumors. It is the first in its class of autologous cellular therapies to demonstrate safety and an overall survival benefit in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer and represents a unique treatment approach that may be further enhanced with other biologic agents, chemotherapy, or checkpoint inhibitors. How sipuleucel-T can be used as a foundation on which to build and enhance future clinical trials will be discussed. © 2016 Elsevier Ltd. All rights reserved. |
